Cowen Lowers Amyris to Neutral (AMRS)

By admin | 6 years ago

Amyris (NASDAQ: AMRS) was downgraded by Cowen from an “outperform” rating to a “neutral” rating in a research note issued on Wednesday.

Several other analysts have also recently commented on the stock. Analysts at Deutsche Bank (NYSE: DB) raised their price target on shares of Amyris to $8.00 in a research note to investors on Tuesday, February 28th. Separately, analysts at ThinkEquity initiated coverage on shares of Amyris in a research note to investors on Wednesday, February 22nd. They set a “hold” rating on the stock. Finally, analysts at Morgan Stanley (NYSE: MS) downgraded shares of Amyris from an “overweight” rating to an “equal weight” rating in a research note to investors on Friday, February 10th. They now have a $13.00 price target on the stock, down previously from $32.00.

Amyris traded up 1.51% on Wednesday, hitting $2.02. Amyris has a 1-year low of $1.89 and a 1-year high of $30.78. The company’s market cap is $101.4 million.

Amyris last released its earnings data on Tuesday, May 8th. The company reported ($1.88) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.76) by $1.12. Amyris’s revenue was down 20.7% compared to the same quarter last year. Analysts expect that Amyris will post $-0.44 EPS next quarter.

Amyris, Inc., formerly Amyris Biotechnologies, Inc. develops and provides renewable compounds for a variety of markets.

About the author